Current developments in the use of engineered bacteria for cancer therapy

CHEN Jiawen; HUANG Jiandong; SUN Haitao

doi:10.12211/2096-8280.2022-062

您当前的位置：

首页 >

文章列表页 >

Current developments in the use of engineered bacteria for cancer therapy

Invited Review | 更新时间：2025-03-20

- Current developments in the use of engineered bacteria for cancer therapy
- Synthetic Biology Journal Vol. 4, Issue 4, Pages: 690-702(2023)
- 作者机构：
  
  1.南方医科大学珠江医院神经外科中心，国家临床重点专科，脑血管病诊断与治疗教育部工程研究中心，广东省普通高校脑功能修复与再生重点实验室，广东神经外科研究所，广东广州 510280
  2.南方医科大学珠江医院检验医学部，临床生物样本资源中心，南方医科大学微生物组医学中心，广东广州 510280
  3.香港大学李嘉诚医学院生物医学学院，生物医学学院，香港 999077
  4.中国科学院深圳先进技术研究院，深圳合成生物学创新研究院，中国科学院定量工程生物学重点实验室，广东省合成基因组学重点实验室，广东深圳 518055
  5.香港大学深圳医院临床肿瘤科，深圳市肿瘤转移与个体化治疗重点实验室，广东深圳518055
  6.粤港RNA医学联合实验室，中山大学，广东广州 510120
- 作者简介：
- 基金信息：
- DOI：10.12211/2096-8280.2022-062
  CLC： Q816
- Received：14 November 2022，
  
  Revised：2023-04-10，
  
  Published：31 August 2023
- 稿件说明：
移动端阅览
陈家文，黄建东，孙海涛. 工程菌在肿瘤治疗方面的应用进展［J］. 合成生物学， 2023， 4（4）： 690-702

CHEN Jiawen， HUANG Jiandong， SUN Haitao. Current developments in the use of engineered bacteria for cancer therapy［J］. Synthetic Biology Journal， 2023， 4（4）： 690-702
陈家文，黄建东，孙海涛. 工程菌在肿瘤治疗方面的应用进展［J］. 合成生物学， 2023， 4（4）： 690-702 DOI： 10.12211/2096-8280.2022-062.

CHEN Jiawen， HUANG Jiandong， SUN Haitao. Current developments in the use of engineered bacteria for cancer therapy［J］. Synthetic Biology Journal， 2023， 4（4）： 690-702 DOI： 10.12211/2096-8280.2022-062.

摘要

肿瘤的细菌治疗最早可以追溯到19世纪，人们第一次利用链球菌（

Streptococcus pyogenes

）成功治疗了患有无法手术切除的肉瘤患者。此后，细菌在肿瘤治疗上的研究越来越多，并取得了令人期待的结果。与其他肿瘤治疗方法相比，细菌治疗肿瘤具有许多独特的优点。随着合成生物学的发展，人们对细菌进行改造后大大增强了其在肿瘤治疗中的运用。本文介绍了细菌改造策略和应用进展，特别是鼠伤寒沙门氏菌治疗肿瘤的研究。在动物模型中，工程菌可以选择性定植到肿瘤组织中并抑制肿瘤的生长。此外，介绍了工程菌治疗肿瘤的新策略——表达抗肿瘤分子来提高肿瘤治疗的效果。最后，讨论了工程菌治疗肿瘤运用于临床还有一些需要解决的问题，如何平衡细菌毒力和抗肿瘤能力是一个关键点，需要设计更精巧的基因线路来对细菌进行改造。在减弱细菌毒力的同时，还要增强细菌靶向到肿瘤组织的能力，以减少对其他正常组织的影响。细菌的遗传不稳定性也是一个潜在的问题，因为突变可能会产生无效或有害的表型。

但是，随着合成生物学的发展，在不久的将来，上述问题将会得到解决，细菌治疗将会是一种具有巨大潜力的肿瘤治疗的方法。

Abstract

Bacterial therapy has a long history

which originated at the end of the 19th century when bacteria were used for the first time to treat cancer. William B. Coley

a bone sarcoma surgeon

used heat-killed

Streptococcus pyogenes

to treat patients with unresectable sarcomas and found that the cancer had disappeared spontaneously. Over the next 40 years

he injected more than 1000 cancer patients with heat-killed bacteria

Streptococcus pyogenes

and

Serratia marcescens

which are now known as Coley's toxins. However

owing to criticism from the medical community

rare reproducibility of the results and the emergence of radiotherapy and chemotherapy

bacterial therapy gradually disappeared from medical practice. With the development of immunology and synthetic biology

bacterial therapy has once again gained importance. Over the past 20 years

bacterial therapy has become a major focus area for research

and several types of bacteria have been used in clinical and preclinical studies. Therefore

bacterial therapy is considered an innovative and ideal strategy to treat cancer. In this review

we summarized the recent progress in the treatment of tumours with genetically engineered bacteria. Various bacteria include

Salmonella

Escherichia coli

Bifidobacterium

and

Streptococcus pyogenes

which can accumulate

especially in tumours

and suppress their growth. However

in order to improve bacterial tumour-targeting ability and reduce bacterial virulence

various bacterial species have been genetically engineered through molecular biology techniques

thus forming different genetically engineered strains by using

Clostridium novyi-NT

Listeria monocytogenes

and

Salmonella typhimurium

. These genetically engineered bacteria can b

e selectively colonized in tumours and can inhibit cancer growth. In addition

they can also be used as live delivery carriers for cancer treatment

which can overcome the limitations of conventional antitumour therapies

such as high toxicity to normal tissue cells and the inability to treat deep tumour tissues. Potential targets including cytokines

cytotoxic agents

regulatory factors

prodrug-converting enzymes and small interfering RNAs (siRNAs) can be delivered via genetically engineered bacteria to treat cancer. However

various problems remain to be overcome before bacterial therapy can be used for clinical cancer treatment. The balance between bacterial virulence and anti-tumor ability is a key point

and more sophisticated genetic circuits need to be designed to modify the bacteria. While reducing the virulence of the bacteria

it is also important to enhance the ability of the bacteria to target to the tumor tissue to reduce the impact on other normal tissues. Genetic instability of bacteria is also a potential problem

as mutations may produce ineffective or deleterious phenotypes. However

with the development of synthetic biology

the above problems would be solved in the future

and bacterial therapy will be an approach with great potential for tumor treatment.

关键词

Keywords

references

WANG D , WEI X D , KALVAKOLANU D V , et al . Perspectives on oncolytic Salmonella in cancer immunotherapy—a promising strategy [J ] . Frontiers in Immunology , 2021 , 12 : 615930 .

MCCARTHY E F . The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas [J ] . The Iowa Orthopaedic Journal , 2006 , 26 : 154 - 158 .

CHOROBIK P , CZAPLICKI D , OSSYSEK K , et al . Salmonella and cancer: from pathogens to therapeutics [J ] . Acta Biochimica Polonica , 2013 , 60 ( 3 ): 285 - 297 .

ZHENG J H , MIN J J . Targeted cancer therapy using engineered Salmonella typhimurium [J ] . Chonnam Medical Journal , 2016 , 52 ( 3 ): 173 - 184 .

PARK S H , ZHENG J H , NGUYEN V H , et al . RGD peptide cell-surface display enhances the targeting and therapeutic efficacy of attenuated Salmonella -mediated cancer therapy [J ] . Theranostics , 2016 , 6 ( 10 ): 1672 - 1682 .

JIANG S N , PHAN T X , NAM T K , et al . Inhibition of tumor growth and metastasis by a combination of Escherichia coli -mediated cytolytic therapy and radiotherapy [J ] . Molecular Therapy , 2010 , 18 ( 3 ): 635 - 642 .

ZHU H , LI Z , MAO S , et al . Antitumor effect of sFlt-1 gene therapy system mediated by Bifidobacterium Infantis on Lewis lung cancer in mice [J ] . Cancer Gene Therapy , 2011 , 18 ( 12 ): 884 - 896 .

MALETZKI C , LINNEBACHER M , KREIKEMEYER B , et al . Pancreatic cancer regression by intratumoural injection of live Streptococcus pyogenes in a syngeneic mouse model [J ] . Gut , 2008 , 57 ( 4 ): 483 - 491 .

ST JEAN A T , ZHANG M M , FORBES N S . Bacterial therapies: completing the cancer treatment toolbox [J ] . Current Opinion in Biotechnology , 2008 , 19 ( 5 ): 511 - 517 .

LIANG K , LIU Q , LI P , et al . Genetically engineered Salmonella typhimurium : recent advances in cancer therapy [J ] . Cancer Letters , 2019 , 448 : 168 - 181 .

ZHOU S B , GRAVEKAMP C , BERMUDES D , et al . Tumour-targeting bacteria engineered to fight cancer [J ] . Nature Reviews Cancer , 2018 , 18 ( 12 ): 727 - 743 .

SZNOL M , LIN S L , BERMUDES D , et al . Use of preferentially replicating bacteria for the treatment of cancer [J ] . The Journal of Clinical Investigation , 2000 , 105 ( 8 ): 1027 - 1030 .

GUO Y X , CHEN Y , LIU X Q , et al . Targeted cancer immunotherapy with genetically engineered oncolytic Salmonella typhimurium [J ] . Cancer Letters , 2020 , 469 : 102 - 110 .

WANG Y X , CHEN J X , TANG B , et al . Systemic administration of attenuated Salmonella typhimurium in combination with interleukin-21 for cancer therapy [J ] . Molecular and Clinical Oncology , 2013 , 1 ( 3 ): 461 - 465 .

KIM S H , CASTRO F , PATERSON Y , et al . High efficacy of a Listeria-based vaccine against metastatic breast cancer reveals a dual mode of action [J ] . Cancer Research , 2009 , 69 ( 14 ): 5860 - 5866 .

董宇轩 , 曾正阳 , 夏霖 , 等 . 肿瘤细菌疗法迎来合成生物学时代 [J ] . 生命科学 , 2019 , 31 ( 4 ): 332 - 342 .

DONG Y X , ZENG Z Y , XIA L , et al . Bacterial anti-cancer therapy in the era of synthetic biology [J ] . Chinese Bulletin of Life Sciences , 2019 , 31 ( 4 ): 332 - 342 .

GANAI S , ARENAS R B , SAUER J P , et al . In tumors Salmonella migrate away from vasculature toward the transition zone and induce apoptosis [J ] . Cancer Gene Therapy , 2011 , 18 ( 7 ): 457 - 466 .

TOSO J F , GILL V J , HWU P , et al . Phase Ⅰ study of the intravenous ad ministration of attenuated Salmonella typhimurium to patients with metastatic melanoma [J ] . Journal of Clinical Oncology , 2002 , 20 ( 1 ): 142 - 152 .

ZHOU S J , ZHAO Z G , LIN Y , et al . Suppression of pancreatic ductal adenocarcinoma growth by intratumoral delivery of attenuated Salmonella typhimurium using a dual fluorescent live tracking system [J ] . Cancer Biology & Therapy , 2016 , 17 ( 7 ): 732 - 740 .

LIU B H , JIANG Y N , DONG T G , et al . Blockage of autophagy pathway enhances Salmonella tumor-targeting [J ] . Oncotarget , 2016 , 7 ( 16 ): 22873 - 22882 .

LI C X , YU B , SHI L , et al . 'Obligate' anaerobic Salmonella strain YB1 suppresses liver tumor growth and metastasis in nude mice [J ] . Oncology Letters , 2017 , 13 ( 1 ): 177 - 183 .

GURBATRI C R , LIA I , VINCENT R , et al . Engineered probiotics for local tumor delivery of checkpoint blockade nanobodies [J ] . Science Translational Medicine , 2020 , 12 ( 530 ): eaax0876 .

LEVENTHAL D S , SOKOLOVSKA A , LI N , et al . Immunotherapy with engineered bacteria by targeting the STING pathway for anti-tumor immunity [J ] . Nature Communications , 2020 , 11 : 2739 .

CANALE F P , BASSO C , ANTONINI G , et al . Metabolic modulation of tumours with engineered bacteria for immunotherapy [J ] . Nature , 2021 , 598 ( 7882 ): 662 - 666 .

KRAMER M G , MASNER M , FERREIRA F A , et al . Bacterial therapy of cancer: promises, limitations, and insights for future directions [J ] . Frontiers in Microbiology , 2018 , 9 : 16 .

RUDER W C , LU T , COLLINS J J . Synthetic biology moving into the clinic [J ] . Science , 2011 , 333 ( 6047 ): 1248 - 1252 .

刘陈立 , 董宇轩 , 郭旋 . 合成生物学在推动肿瘤细菌疗法临床药物开发中的应用 [J ] . 集成技术 , 2021 , 10 ( 4 ): 78 - 92 .

LIU C L , DONG Y X , GUO X . Application of synthetic biology in promoting preclinical and clinical advances of bacterial anti-cancer therapy [J ] . Journal of Integration Technology , 2021 , 10 ( 4 ): 78 - 92 .

STIRLING F , BITZAN L , O'KEEFE S , et al . Rational design of evolutionarily stable microbial kill switches [J ] . Molecular Cell , 2017 , 68 ( 4 ): 686 - 697.e3 .

CHAN C T Y , LEE J W , CAMERON D E , et al . 'Deadman' and 'Passcode' microbial kill switches for bacterial containment [J ] . Nature Chemical Biology , 2016 , 12 ( 2 ): 82 - 86 .

AUSLÄNDER S , AUSLÄNDER D , FUSSENEGGER M . Synthetic biology—the synthesis of biology [J ] . Angewandte Chemie International Edition , 2017 , 56 ( 23 ): 6396 - 6419 .

DANINO T , MONDRAGÓN-PALOMINO O , TSIMRING L , et al . A synchronized quorum of genetic clocks [J ] . Nature , 2010 , 463 ( 7279 ): 326 - 330 .

DIN M O , DANINO T , PRINDLE A , et al . Synchronized cycles of bacterial lysis for in vivo delivery [J ] . Nature , 2016 , 536 ( 7614 ): 81 - 85 .

WANG B J , KITNEY R I , JOLY N , et al . Engineering modular and orthogonal genetic logic gates for robust digital-like synthetic biology [J ] . Nature Communications , 2011 , 2 : 508 .

LIU Y C , ZENG Y Y , LIU L , et al . Synthesizing AND gate genetic circuits based on CRISPR-Cas9 for identification of bladder cancer cells [J ] . Nature Communications , 2014 , 5 : 5393 .

FORBES N S . Engineering the perfect (bacterial) cancer therapy [J ] . Nature Reviews Cancer , 2010 , 10 ( 11 ): 785 - 794 .

PATRA S , PRADHAN B , NAYAK R , et al . Apoptosis and autophagy modulating dietary phytochemicals in cancer therapeutics: current evidences and future perspectives [J ] . Phytotherapy Research , 2021 , 35 ( 8 ): 4194 - 4214 .

YANG S Y , FAN W G , LI Y Y , et al . Autophagy in tooth: physiology, disease and therapeutic implication [J ] . Cell Biochemistry and Function , 2021 , 39 ( 6 ): 702 - 712 .

LEE C H , LIN S T , LIU J J , et al . Salmonella induce autophagy in melanoma by the downregulation of AKT/mTOR path way [J ] . Gene Therapy , 2014 , 21 ( 3 ): 309 - 316 .

ALIZADEH S , ESMAEILI A , OMIDI Y . Anti-cancer properties of Escherichia coli Nissle 1917 against HT-29 colon cancer cells through regulation of Bax/Bcl-xL and AKT/PTEN signaling pathways [J ] . Iranian Journal of Basic Medical Sciences , 2020 , 23 ( 7 ): 886 - 893 .

SHINNOH M , HORINAKA M , YASUDA T , et al . Clostridium butyricum MIYAIRI 588 shows antitumor effects by enhancing the release of TRAIL from neutrophils through MMP-8 [J ] . International Journal of Oncology , 2013 , 42 ( 3 ): 903 - 911 .

DOBROVOLSKAIA M A , VOGEL S N , et al . Toll receptors, CD14, and macrophage activation and deactivation by LPS [J ] . Microbes and Infection , 2002 , 4 ( 9 ): 903 - 914 .

PHAN T X , NGUYEN V H , DUONG M T Q , et al . Activation of inflammasome by attenuated Salmonella typhimurium in bacteria-mediated cancer therapy [J ] . Microbiology and Immunology , 2015 , 59 ( 11 ): 664 - 675 .

KIM J E , PHAN T X , NGUYEN V H , et al . Salmonella typhimurium suppresses tumor growth via the pro-inflammatory cytokine interleukin-1β [J ] . Theranostics , 2015 , 5 ( 12 ): 1328 - 1342 .

CAI Z Y , SANCHEZ A , SHI Z C , et al . Activation of Toll-like receptor 5 on breast cancer cells by flagellin suppresses cell proliferation and tumor growth [J ] . Cancer Research , 2011 , 71 ( 7 ): 2466 - 2475 .

SFONDRINI L , ROSSINI A , BESUSSO D , et al . Antitumor activity of the TLR-5 ligand flagellin in mouse models of cancer [J ] . Journal of Immunology , 2006 , 176 ( 11 ): 6624 - 6630 .

LIN Q B , RONG L , JIA X , et al . IFN-γ-dependent NK cell activation is essential to metastasis suppression by engineered Salmonella [J ] . Nature Communications , 2021 , 12 : 2537 .

CHANDRA D , JAHANGIR A , QUISPE-TINTAYA W , et al . Myeloid-derived suppressor cells have a central role in attenuated Listeria monocytogenes -based immunotherapy against metastatic breast cancer in young and old mice [J ] . British Journal of Cancer , 2013 , 108 ( 11 ): 2281 - 2290 .

JAHANGIR A , CHANDRA D , QUISPE-TINTAYA W , et al . Immunotherapy with Listeria reduces metastatic breast cancer in young and old mice through different mechanisms [J ] . OncoImmunology , 2017 , 6 ( 9 ): e1342025 .

SEDIGHI M , ZAHEDI BIALVAEI A , HAMBLIN M R , et al . Therapeutic bacteria to combat cancer; current advances, challenges, and opportunities [J ] . Cancer Medicine , 2019 , 8 ( 6 ): 3167 - 3181 .

SALTZMAN D A , KATSANIS E , HEISE C P , et al . Antitumor mechanisms of attenuated Salmonella typhimurium containing the gene for human interleukin-2: a novel antitumor agent? [J ] . Journal of Pediatric Surgery , 1997 , 32 ( 2 ): 301 - 306 .

SORENSON B S , BANTON K L , FRYKMAN N L , et al . Attenuated Salmonella typhimurium with IL-2 gene reduces pulmonary metastases in murine osteosarcoma [J ] . Clinical Orthopaedics & Related Research , 2008 , 466 ( 6 ): 1285 - 1291 .

SORENSON B S , BANTON K L , FRYKMAN N L . Attenuated Salmonella typhimurium with interleukin 2 gene prevents the establishment of pulmonary metastases in a model of osteosarcoma [J ] . Journal of Pediatric Surgery , 2008 , 43 ( 6 ): 1153 - 1158 .

ZHANG Y L , LÜ R , CHANG Z S , et al . Clostridium sporogenes delivers interleukin-12 to hypoxic tumours, producing antitumour activity without significant toxicity [J ] . Letters in Applied Microbiology , 2014 , 59 ( 6 ): 580 - 586

AL-RAMADI B K , FERNANDEZ-CABEZUDO M J , EL-HASASNA H , et al . Potent anti-tumor activity of systemically-administered IL2-expressing Salmonella correlates with decreased angiogenesis and enhanced tumor apoptosis [J ] . Clinical Immunology , 2009 , 130 ( 1 ): 89 - 97 .

BARBÉ S , VAN MELLAERT L , THEYS J , et al . Secretory production of biologically active rat interleukin-2 by Clostridium acetobutylicum DSM792 as a tool for anti-tumor treatment [J ] . FEMS Microbiology Letters , 2005 , 246 ( 1 ): 67 - 73 .

LOEFFLER M , LE'NEGRATE G , KRAJEWSKA M , et al . Salmonella typhimurium engineered to produce CCL21 inhibit tumor growth [J ] . Cancer Immunology, Immunotherapy , 2009 , 58 ( 5 ): 769 - 775 .

LOEFFLER M , LE'NEGRATE G , KRAJEWSKA M , et al . IL-18-producing Salmonella inhibit tumor growth [J ] . Cancer Gene Therapy , 2008 , 15 ( 12 ): 787 - 794 .

CHEN J X , YANG B Y , CHENG X W , et al . Salmonella -mediated tumor-targeting TRAIL gene therapy significantly suppresses melanoma growth in mouse model [J ] . Cancer Science , 2012 , 103 ( 2 ): 325 - 333 .

GANAI S , ARENAS R B , FORBES N S . Tumour-targeted delivery of TRAIL using Salmonella typhimurium enhances breast cancer survival in mice [J ] . British Journal of Cancer , 2009 , 101 ( 10 ): 1683 - 1691 .

LIANG K , LIU Q , LI P , et al . Endostatin gene therapy delivered by attenuated Salmonella typhimurium in murine tumor models [J ] . Cancer Gene Therapy , 2018 , 25 ( 7 ): 167 - 183 .

LEE C H , WU C L , SHIAU A L . Endostatin gene therapy delivered by Salmonella choleraesuis in murine tumor models [J ] . The Journal of Gene Medicine , 2004 , 6 ( 12 ): 1382 - 1393 .

NGUYEN V H , KIM H S , HA J M , et al . Genetically engineered Salmonella typhimurium as an imageable therapeutic probe for cancer [J ] . Cancer Research , 2010 , 70 ( 1 ): 18 - 23 .

LOEFFLER M , LE'NEGRATE G , KRAJEWSKA M , et al . Inhibition of tumor growth using Salmonella expressing fas ligand [J ] . Journal of the National Cancer Institute , 2008 , 100 ( 15 ): 1113 - 1116 .

MANSOUR M , ISMAIL S , ABOU-AISHA K . Bacterial delivery of the anti-tumor azurin-like protein Laz to glioblastoma cells [J ] . AMB Express , 2020 , 10 ( 1 ): 59 .

Wen M , Zheng J H , Choi J M , et al . Genetically-engineered Salmonella typhimurium expressing TIMP-2 as a therapeutic intervention in an orthotopic glioma mouse model [J ] . Cancer Letters , 2018 , 433 : 140 - 146 .

HE L , YANG H J , LIU F , et al . Escherichia coli Nissle 1917 engineered to express Tum-5 can restrain murine melanoma growth [J ] . Oncotarget , 2017 , 8 ( 49 ): 85772 - 85782 .

HE L , YANG H J , TANG J L , et al . Intestinal probiotics E. coli Nissle 1917 as a targeted vehicle for delivery of p53 and Tum-5 to solid tumors for cancer therapy [J ] . Journal of Biological Engineering , 2019 , 13 : 58 .

NEJMAN D , LIVYATAN I , FUKS G , et al . The human tumor microbiome is composed of tumor type-specific intracellular bacteria [J ] . Science , 2020 , 368 ( 6494 ): 973 - 980 .

LIU S C , MINTON N , GIACCIA A , et al . Anticancer efficacy of systemically delivered anaerobic bacteria as gene therapy vectors targeting tumor hypoxia/necrosis [J ] . Gene Therapy , 2002 , 9 ( 4 ): 291 - 296 .

KING I , BERMUDES D , LIN S , et al . Tumor-targeted Salmonella expressing cytosine deaminase as an anticancer agent [J ] . Human Gene Therapy , 2002 , 13 ( 10 ): 1225 - 1233 .

FRIEDLOS F , LEHOURITIS P , OGILVIE L , et al . Attenuated Salmonella targets prodrug activating enzyme carboxypeptidase G2 to mouse melanoma and human breast and colon carcinomas for effective suicide gene therapy [J ] . Clinical Cancer Research , 2008 , 14 ( 13 ): 4259 - 4266 .

FU W , LAN H , LI S , et al . Synergistic antitumor efficacy of suicide/ePNP gene and 6-methylpurine 2′-deoxyriboside via Salmonella against murine tumors [J ] . Cancer Gene Therapy , 2008 , 15 ( 7 ): 474 - 484 .

LIU S C , AHN G O , KIOI M , et al . Optimized Clostridium -directed enzyme prodrug therapy improves the antitumor activity of the novel DNA cross-linking agent PR-104 [J ] . Cancer Research , 2008 , 68 ( 19 ): 7995 - 8003 .

WANG J , LU Z , WIENTJESET M G , al . Delivery of siRNA therapeutics: barriers and carriers [J ] . The AAPS Journal , 2010 , 12 ( 4 ): 492 - 503 .

SAJID M I , MOAZZAM M , KATO S , et al . Overcoming barriers for siRNA therapeutics: from bench to bedside [J ] . Pharmaceuticals , 2020 , 13 ( 10 ): 294 .

GU J L , LI Y , ZENG J , et al . Knockdown of HIF-1α by siRNA-expressing plasmid delivered by attenuated Salmonella enhances the antitumor effects of cisplatin on prostate cancer [J ] . Scientific Reports , 2017 , 7 : 7546 .

AI Z H , LU Y , QIU S B , et al . Overcoming cisplatin resistance of ovarian cancer cells by targeting HIF-1-regulated cancer metabolism [J ] . Cancer Letters , 2016 , 373 ( 1 ): 36 - 44 .

PARDOLL D M . The blockade of immune checkpoints in cancer immunotherapy [J ] . Nature Reviews Cancer , 2012 , 12 ( 4 ): 252 - 264 .

ZHAO T S , WEI T , GUO J , et al . PD-1-siRNA delivered by attenuated Salmonella enhances the antimelanoma effect of pimozide [J ] . Cell Death & Disease , 2019 , 10 ( 3 ): 164 .

TURAJLIC S , SWANTON C . Metastasis as an evolutionary process [J ] . Science , 2016 , 352 ( 6282 ): 169 - 175 .

KORSMEYER S J . BCL-2 gene family and the regulation of programmed cell death [J ] . Cancer Research , 1999 , 59 ( 7 Suppl ): 1693s - 1700s .

HAFEZI S , RAHMANI M . Targeting BCL-2 in cancer: advances, challenges, and perspectives [J ] . Cancers , 2021 , 13 ( 6 ): 1292 .

YANG N , ZHU X Y , CHEN L S , et al . Oral administration of attenuated S. typhimurium carrying shRNA-expressing vectors as a cancer therapeutic [J ] . Cancer Biology & Therapy , 2008 , 7 ( 1 ): 145 - 151 .

PHAM T H , PARK H M , KIM J , et al . STAT3 and p53: dual target for cancer therapy [J ] . Biomedicines , 2020 , 8 ( 12 ): 637 .

KUAN Y D , LEE C H . Salmonella overcomes tumor immune tolerance by inhibition of tumor indoleamine 2, 3-dioxygenase 1 expression [J ] . Oncotarget , 2016 , 7 ( 1 ): 374 - 385 .

BLACHE C A , MANUEL E R , KALTCHEVA T I , et al . Systemic delivery of Salmonella typhimurium transformed with IDO shRNA enhances intratumoral vector colonization and suppresses tumor growth [J ] . Cancer Research , 2012 , 72 ( 24 ): 6447 - 6456 .

O'DONNELL J S , LONG G V , SCOLYER R A , et al . Resistance to PD1/PDL1 checkpoint inhibition [J ] . Cancer Treatment Reviews , 2017 , 52 : 71 - 81 .

IWAI Y , HAMANISHI J , CHAMOTO K , et al . Cancer immunotherapies targeting the PD-1 signaling pathway [J ] . Journal of Biomedical Science , 2017 , 24 ( 1 ): 26 .

CHOWDHURY S , CASTRO S , COKER C , et al . Programmable bacteria induce durable tumor regression and systemic antitumor immunity [J ] . Nature Medicine , 2019 , 25 ( 7 ): 1057 - 1063 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Applications of vector vaccines developed through T-cell immune responses in preventing and treating human diseases

Progress of bispecific antibodies and nanotechnology in tumor immunotherapies

Related Author

HUANG Jiandong

JIANG Shasha

WANG Chen

LU Ran

LIU Fengjun

LI Jun

WANG Bin

XU Shilin

Related Institution

Hong Kong Joint Laboratory for RNA Medicine， Sun Yat-Sen University，， Guangdong

Department of Special Medicine， School of Basic Medicine， Qingdao University

Microbiological Laboratory， Chaoyang District Center for Disease Control and Prevention

Department of Pathogenic Biology， School of Basic Medicine， Qingdao University

Institute of Basic Medical Sciences，Chinese Academy of Medical Sciences & Peking Union Medical College

⁰